Emergent facility to work on TB, typhoid vaccines

Emergent BioSolutions plans to renovate a 55,000-square-foot facility. The facility isn't slated to open until 2012; however, upon its completion, the expansion will not only give Emergent more space to fill government contracts for BioThrax, but also will allow the developer to start testing commercial vaccines for ailments like tuberculosis and typhoid. Report

Editor's Note: Article modified to remove "in Baltimore" from first sentence.

Suggested Articles

The pandemic price could be lowered for larger deals, CEO Stephane Bancel said. Pfizer and BioNTech priced 100M doses at $19.50 each for the U.S.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Sanofi's cost cuts are adding up, execs said in an update Wednesday. The company has trimmed nearly €1 billion in annual expenses so far in 2020.